close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

45.11 -0.23 (-0.51%)
Official Closing Price Updated: 4:15 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma ↗
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma. 
Via Benzinga
News headline image
Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share was... 
Via StockStory
News headline image
Royalty Pharma Reports Q4 and Full Year 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Insights Ahead: Royalty Pharma's Quarterly Earnings ↗
 
Via Benzinga
News headline image
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday? ↗
U.S. 
Via Benzinga
News headline image
Royalty Pharma Earnings: What To Look For From RPRX
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
News headline image
Earnings Scheduled For February 11, 2025 ↗
 
Via Benzinga
News headline image
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
News headline image
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio? ↗
Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United... 
Via Benzinga
News headline image
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock ↗
Jim Cramer likes Walmart (WMT). Walmart provides body cameras to employees in a pilot program. Cramer says Royalty Pharma (RPRX) is a disappointing stock. 
Via Benzinga
News headline image
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips ↗
Via The Motley Fool
News headline image
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade ↗
Via The Motley Fool
News headline image
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
Royalty Pharma Reports Third Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income ↗
Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire. 
Via The Motley Fool
News headline image
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Fourth Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today